Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Tsiskaridze, Alexander
NIMBLE, NCT05070858 / 2020-003272-41: A Study to Examine the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Adult Patients With Symptomatic Generalized Myasthenia Gravis	Recruiting	3	235	Europe, Canada, Japan, US, RoW	Pozelimab + Cemdisiran, Cemdisiran, ALN-CC5, Placebo, Pozelimab, REGN3918	Regeneron Pharmaceuticals	Generalized Myasthenia Gravis	08/25	03/28
ENSURE-1, NCT05134441: Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis	Recruiting	3	1050	Europe, US, RoW	IMU-838 tablets, vidofludimus calcium, Placebo matching IMU-838 tablets, Placebo matching vidofludimus calcium	Immunic AG	Multiple Sclerosis	09/24	09/32
PULSE-F, NCT05577351: Feasibility Study of RapidPulseTM Aspiration System as Frontline Approach for Patients With Acute Ischemic Stroke	Completed	N/A	5	RoW	RapidPulseTM Aspiration System, Aspiration Thrombectomy	RapidPulse, Inc	Acute Ischemic Stroke	06/23	06/23
PULSE-C, NCT05899036: Early Feasibility Study of RapidPulseTM Aspiration System for Patients With Acute Ischemic Stroke	Recruiting	N/A	10	RoW	RapidPulseTM Aspiration System, Aspiration Thrombectomy, Thrombectomy	RapidPulse, Inc	Acute Ischemic Stroke, Stroke, Large Vessel Occlusion, Mechanical Thrombectomy	06/24	07/24
Guldedava, Nana
ENSURE-1, NCT05134441: Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis	Recruiting	3	1050	Europe, US, RoW	IMU-838 tablets, vidofludimus calcium, Placebo matching IMU-838 tablets, Placebo matching vidofludimus calcium	Immunic AG	Multiple Sclerosis	09/24	09/32